AGT and triple-A syndrome: Using the angiotensin II (Ang II)–induced model of AAA formation in Apoe−/− mice fed a high-fat diet,20 we investigated the potential beneficial effects of miR-181b inhibition on the progression of infrarenal atherosclerotic AAAs by using the protocol described in Online Figure X. Treatment with an miR-181b inhibitor did not alter mean arterial blood pressure levels in response to Ang II infusion (Figure 4A) but significantly reduced the occurrence of AAAs to 48% from 86% in scrambled inhibitor-infused, control mice (Figure 4B).